Plain-English translation of NCT04587687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications— and bendamustine—work better together to treat follicular lymphoma that has either come back after treatment or stopped responding to previous medications. Follicular lymphoma is a type of blood cancer that grows in lymph nodes. The study wants to see how many people respond well to this two-drug combination and how long the improvement lasts.
Follicular lymphoma often comes back or stops responding to standard treatments, leaving patients with limited options. This medication combination has shown promise in early testing, and researchers want to learn whether giving both drugs together can help more patients achieve long-lasting remission.
You likely qualify if…
You likely don't qualify if…
You will receive two intravenous medications on a repeating schedule: one medication on day 1 and the other on days 1 and 2 of each 3-week cycle. You'll receive 6 cycles of the combination (about 18 weeks). If your cancer responds well and you tolerate the treatment, you may continue receiving one of the medications alone for up to 10 more cycles. You'll have regular blood tests and imaging scans to monitor your progress, plus follow-up visits for 2 years after treatment ends.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States